Decoy Therapeutics Inc.
For the period ended Dec 31, 2024. Filed Mar 21, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 21, 2025
DCOY$1.10-2.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| 2024 | 2023 | |
|---|---|---|
| Operating expenses: | ||
| Research and development | 770,027 | 7,173,747 |
| General and administrative | 4,964,289 | 5,721,197 |
| Total operating expenses | 5,734,316 | 12,894,944 |
| Loss before other income (expense) | (5,734,316) | (12,894,944) |
| Interest income | 158,539 | 352,251 |
| Net loss | $(5,575,777) | $(12,542,693) |
| Loss attributable to common stockholders | $(5,575,777) | $(12,542,693) |
| Loss per common share — basic and diluted | $(5.79) | $(30.74) |
| Total net loss per share | $(5.79) | $(30.74) |
| Weighted-average number of common shares outstanding — basic and diluted | 962,210 | 408,078 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.